Which has higher valuation & earnings, TELO or ATOS?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A Atossa Genetics N/A N/A -$34.77M -$3.11 N/A

Is TELO or ATOS more profitable?

Telomir Pharmaceuticals' return on equity of -102.70% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -102.70% -90.75% Atossa Genetics N/A -102.99% -85.78%

Does the media prefer TELO or ATOS?

In the previous week, Atossa Genetics had 7 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 10 mentions for Atossa Genetics and 3 mentions for Telomir Pharmaceuticals. Atossa Genetics' average media sentiment score of 0.80 beat Telomir Pharmaceuticals' score of 0.35 indicating that Atossa Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GUTS or ATOS more profitable?

Atossa Genetics' return on equity of -102.99% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Atossa Genetics N/A -102.99% -85.78%

Does the media refer more to GUTS or ATOS?

In the previous week, Fractyl Health had 10 more articles in the media than Atossa Genetics. MarketBeat recorded 20 mentions for Fractyl Health and 10 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.80 beat Fractyl Health's score of -0.08 indicating that Atossa Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 0 Very Positive mention(s) 0 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, PMVP or ATOS?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A Atossa Genetics N/A N/A -$34.77M -$3.11 N/A

Is PMVP or ATOS more profitable?

PMV Pharmaceuticals' return on equity of -78.11% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -78.11% -70.13% Atossa Genetics N/A -102.99% -85.78%

Does the media favor PMVP or ATOS?

In the previous week, Atossa Genetics had 8 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 10 mentions for Atossa Genetics and 2 mentions for PMV Pharmaceuticals. Atossa Genetics' average media sentiment score of 0.80 beat PMV Pharmaceuticals' score of -0.83 indicating that Atossa Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Atossa Genetics (ATOS) Competitors

$2.44 +0.02 (+0.83%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 +0.06 (+2.50%)

As of 07:59 PM Eastern

Compare

ATOS vs. TELO, ATRA, SERA, GUTS, and PMVP

Should you buy Atossa Genetics stock or one of its competitors? Atossa Genetics's main competitors and comparable companies include Telomir Pharmaceuticals (TELO), Atara Biotherapeutics (ATRA), Sera Prognostics (SERA), Fractyl Health (GUTS), and PMV Pharmaceuticals (PMVP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Atossa Genetics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

12.7% of Atossa Genetics shares are held by institutional investors. 16.4% of Telomir Pharmaceuticals shares are held by insiders. Comparatively, 9.8% of Atossa Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Telomir Pharmaceuticals' return on equity of -102.70% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%
Atossa Genetics	N/A	-102.99%	-85.78%

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A

Telomir Pharmaceuticals has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Telomir Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 247.83%. Atossa Genetics has a consensus target price of $20.33, suggesting a potential upside of 740.22%. Given Atossa Genetics' higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Atossa Genetics had 7 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 10 mentions for Atossa Genetics and 3 mentions for Telomir Pharmaceuticals. Atossa Genetics' average media sentiment score of 0.80 beat Telomir Pharmaceuticals' score of 0.35 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telomir Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atossa Genetics beats Telomir Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Atossa Genetics compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Atara Biotherapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Atossa Genetics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.77	$32.69M	-$1.18	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Atossa Genetics had 10 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 10 mentions for Atossa Genetics and 0 mentions for Atara Biotherapeutics. Atossa Genetics' average media sentiment score of 0.80 beat Atara Biotherapeutics' score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
Atossa Genetics	Positive

Atara Biotherapeutics currently has a consensus price target of $9.50, indicating a potential upside of 2.93%. Atossa Genetics has a consensus price target of $20.33, indicating a potential upside of 740.22%. Given Atossa Genetics' higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Atossa Genetics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Atara Biotherapeutics' return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	N/A	-73.01%
Atossa Genetics	N/A	-102.99%	-85.78%

Summary

Atara Biotherapeutics beats Atossa Genetics on 9 of the 16 factors compared between the two stocks.

How does Atossa Genetics compare to Sera Prognostics?

Atossa Genetics (NASDAQ:ATOS) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Atossa Genetics presently has a consensus price target of $20.33, suggesting a potential upside of 740.22%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 172.28%. Given Atossa Genetics' higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sera Prognostics has higher revenue and earnings than Atossa Genetics. Sera Prognostics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Sera Prognostics	$80K	996.11	-$31.93M	-$0.67	N/A

Atossa Genetics has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Atossa Genetics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

In the previous week, Atossa Genetics had 10 more articles in the media than Sera Prognostics. MarketBeat recorded 10 mentions for Atossa Genetics and 0 mentions for Sera Prognostics. Atossa Genetics' average media sentiment score of 0.80 beat Sera Prognostics' score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Atossa Genetics	Positive
Sera Prognostics	Neutral

Summary

Sera Prognostics beats Atossa Genetics on 9 of the 16 factors compared between the two stocks.

How does Atossa Genetics compare to Fractyl Health?

Fractyl Health (NASDAQ:GUTS) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

12.7% of Atossa Genetics shares are held by institutional investors. 8.4% of Fractyl Health shares are held by company insiders. Comparatively, 9.8% of Atossa Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Atossa Genetics has lower revenue, but higher earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	623.22	-$140.95M	-$0.88	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A

In the previous week, Fractyl Health had 10 more articles in the media than Atossa Genetics. MarketBeat recorded 20 mentions for Fractyl Health and 10 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.80 beat Fractyl Health's score of -0.08 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	0 Very Positive mention(s)	0 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fractyl Health has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Atossa Genetics' return on equity of -102.99% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Atossa Genetics	N/A	-102.99%	-85.78%

Fractyl Health currently has a consensus price target of $66.00, suggesting a potential upside of 1,460.28%. Atossa Genetics has a consensus price target of $20.33, suggesting a potential upside of 740.22%. Given Fractyl Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe Fractyl Health is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Fractyl Health beats Atossa Genetics on 8 of the 13 factors compared between the two stocks.

How does Atossa Genetics compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

PMV Pharmaceuticals' return on equity of -78.11% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
Atossa Genetics	N/A	-102.99%	-85.78%

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A

PMV Pharmaceuticals currently has a consensus price target of $4.33, suggesting a potential upside of 190.83%. Atossa Genetics has a consensus price target of $20.33, suggesting a potential upside of 740.22%. Given Atossa Genetics' higher probable upside, analysts clearly believe Atossa Genetics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 10.2% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 9.8% of Atossa Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Atossa Genetics had 8 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 10 mentions for Atossa Genetics and 2 mentions for PMV Pharmaceuticals. Atossa Genetics' average media sentiment score of 0.80 beat PMV Pharmaceuticals' score of -0.83 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PMV Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PMV Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Summary

PMV Pharmaceuticals beats Atossa Genetics on 8 of the 13 factors compared between the two stocks.

Get Atossa Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATOS vs. The Competition

Export

Metric	Atossa Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.15M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	20.71%
P/E Ratio	-0.78	13.42	274.13	26.16
Price / Sales	N/A	1,225.48	587.04	94.78
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	0.53	17.17	11.21	6.34
Net Income	-$34.77M	-$22.69M	$3.50B	$381.90M
7 Day Performance	4.27%	-1.20%	-0.84%	-1.39%
1 Month Performance	1.67%	-9.68%	-5.42%	-4.31%
1 Year Performance	-86.21%	10.09%	4.38%	-0.35%

Atossa Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATOS Atossa Genetics	2.3348 of 5 stars	$2.44 +0.8%	$20.33 +733.3%	-85.5%	$24.15M	N/A	N/A	14	News Coverage Analyst Revision High Trading Volume
TELO Telomir Pharmaceuticals	2.1582 of 5 stars	$1.18 -1.7%	$4.00 +239.0%	-30.3%	$81.16M	N/A	N/A	5
ATRA Atara Biotherapeutics	1.9698 of 5 stars	$8.07 -3.6%	$9.50 +17.7%	-41.8%	$81.02M	$120.77M	N/A	330	News Coverage
SERA Sera Prognostics	1.7067 of 5 stars	$2.04 +0.7%	$5.50 +170.3%	-35.9%	$80.28M	$80K	N/A	72
GUTS Fractyl Health	2.6205 of 5 stars	$0.48 +2.3%	$5.50 +1,041.1%	-74.8%	$76.73M	$90K	N/A	73

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATOS) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atossa Genetics (ATOS) Competitors

ATOS vs. TELO, ATRA, SERA, GUTS, and PMVP

How does Atossa Genetics compare to Telomir Pharmaceuticals?

Summary

How does Atossa Genetics compare to Atara Biotherapeutics?

Summary

How does Atossa Genetics compare to Sera Prognostics?

Summary

How does Atossa Genetics compare to Fractyl Health?

Summary

How does Atossa Genetics compare to PMV Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atossa Genetics (ATOS) Competitors

ATOS vs. TELO, ATRA, SERA, GUTS, and PMVP

How does Atossa Genetics compare to Telomir Pharmaceuticals?

Do institutionals & insiders have more ownership in TELO or ATOS?

Is TELO or ATOS more profitable?

Which has higher valuation & earnings, TELO or ATOS?

Which has more volatility & risk, TELO or ATOS?

Do analysts rate TELO or ATOS?

Does the media prefer TELO or ATOS?

Summary

How does Atossa Genetics compare to Atara Biotherapeutics?

Which has more risk and volatility, ATRA or ATOS?

Which has higher valuation & earnings, ATRA or ATOS?

Do institutionals & insiders hold more shares of ATRA or ATOS?

Does the media prefer ATRA or ATOS?

Do analysts prefer ATRA or ATOS?

Is ATRA or ATOS more profitable?

Summary

How does Atossa Genetics compare to Sera Prognostics?

Do insiders & institutionals have more ownership in ATOS or SERA?

Do analysts recommend ATOS or SERA?

Which has better valuation & earnings, ATOS or SERA?

Which has more volatility & risk, ATOS or SERA?

Is ATOS or SERA more profitable?

Does the media prefer ATOS or SERA?

Summary

How does Atossa Genetics compare to Fractyl Health?

Do insiders & institutionals hold more shares of GUTS or ATOS?

Which has higher valuation and earnings, GUTS or ATOS?

Does the media refer more to GUTS or ATOS?

Which has more volatility and risk, GUTS or ATOS?

Is GUTS or ATOS more profitable?

Do analysts rate GUTS or ATOS?

Summary

How does Atossa Genetics compare to PMV Pharmaceuticals?

Is PMVP or ATOS more profitable?

Which has higher earnings and valuation, PMVP or ATOS?

Do analysts rate PMVP or ATOS?

Do institutionals & insiders believe in PMVP or ATOS?

Does the media favor PMVP or ATOS?

Which has more volatility & risk, PMVP or ATOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools